Dapagliflozin reduces heart failure in diabetes

Dapagliflozin reduces heart failure in diabetes

CHICAGO – dapagliflozin (Farxiga / ForxigaAstraZeneca) showed a non-significant trend toward a reduced rate of major cardiac events (MACE) in patients with type 2 diabetes in the DECLARE-TIMI 58 study.

The study was presented here in the Scientific Sessions 2018 of the American Heart Association (AHA) by lead author Stephen Wiviott, MD, Brigham and Womens Hospital and Harvard Medical School, Boston, Massachusetts. It was also published online on the internet New England Journal of Medicine,

"What we see in this study is a similar topic to other important studies with sodium glucose cotransporter-2 (SGLT2) inhibitors – a significant reduction in hospital insufficiency and kidney disease in heart failure, "commented Wiviott theheart.org | Medscape cardiology.

"DECLARE-TIMI 58, however, is different from the others [cardiovascular outcomes] Studies that included a much broader and healthier population, including 10,000 patients without pre-existing multiple-risk cardiovascular disease and 7,000 patients with pre-existing cardiovascular disease. "

"We found that the benefits of dapagliflozin in heart failure were similar in patients with and without pre-existing cardiovascular disease, whereas the effect on MACE could be differentiated between these populations, without this in the primary prevention group and the trend towards a reduction in those with secondary prevention.

"All three SGLT2-Inhbitor studies have found a major impact on the outcome of heart failure, and our study complements well-known literature in this regard, but it also extends the benefits of heart failure to the diabetic population of primary prevention," said Wiviott.

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.